H-VLSNDVCAQV-OH

Ref. 3D-PP47046

Informations sur le produit

• Nom: H-VLSNDVCAQV-OH
• Synonymes: NH2-Val-Leu-Ser-Asn-Asp-Val-Cys-Ala-Gln-Val-OH

Description

Peptide H-VLSNDVCAQV-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-VLSNDVCAQV-OH include the following: Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing SR Gameiro , ML Jammed, MM Wattenberg, KY Tsang - Oncotarget, 2014 - ncbi.nlm.nih.govhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3964216/ Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells SR Gameiro , AS Malamas, KY Tsang, S Ferrone - Oncotarget, 2016 - ncbi.nlm.nih.govhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4884926/ Provision of Continuous Maturation Signaling to Dendritic Cells by RIG-I-Stimulating Cytosolic RNA Synthesis of Sendai Virus S Okano, Y Yonemitsu , K Shirabe, Y Kakeji - The Journal of , 2011 - journals.aai.orghttps://journals.aai.org/jimmunol/article/186/3/1828/84990 Long-term follow-up of prostate cancer patients treated with vaccine and definitive radiation therapy M Kamrava, AH Kesarwala, RA Madan , E Lita - Prostate cancer and , 2012 - nature.comhttps://www.nature.com/articles/pcan20127 Real time detection of peptide-MHC dissociation reveals that improvement of primary MHC-binding residues can have a minimal, or no, effect on stability KM Miles, JJ Miles , F Madura, AK Sewell , DK Cole - Molecular immunology, 2011 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0161589010006073 Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death JW Hodge , CT Garnett , B Farsaci - journal of cancer, 2013 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.28070 Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 T-cell response to the native peptide PSA: 154-163 but DV Kouiavskaia, CA Berard, E Datena - Journal of , 2009 - journals.lww.comhttps://journals.lww.com/immunotherapy-journal/fulltext/2009/07000/Phase_2_Trial_of_Vaccination_With_Tyrosinase.12.aspx Peptide-based therapeutics in cancer therapy AT Jalil, MA Abdulhadi , LR Al-Ameer , WM Taher - Molecular , 2023 - Springerhttps://link.springer.com/article/10.1007/s12033-023-00873-1 The bright side of chemistry: Exploring synthetic peptide-based anticancer vaccines A D'Aniello, A Del Bene, S Mottola - Journal of Peptide , 2024 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/psc.3596 Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway A Ardiani, SR Gameiro , AR Kwilas, RN Donahue - Oncotarget, 2014 - ncbi.nlm.nih.govhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4253438/

• Marque: Biosynth